Apollon Formularies agrees 28-day extension for asset sale

(Alliance News) - Apollon Formularies PLC on Tuesday said it has agreed a 28-day extension to ...

Alliance News 21 March, 2023 | 4:21PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Apollon Formularies PLC on Tuesday said it has agreed a 28-day extension to complete final due diligence in order to conclude its sale to Global Hemp Group Inc.

The London-based medical cannabis pharmaceutical firm expects the asset sale to take place by April 28, subject to shareholder approval at Apollon's general meeting on April 11.

The agreed extension will allow for the final inspection of Apollon’s facilities in Jamaica, Apollon added.

As part of this process, the company said Stephen Barnhill Jnr has stepped down from his current role as non-board chief operating officer of Apollon. He will join Global Hemp as its interim as its interim chief executive officer.

"He will be instrumental in helping to complete the current process," Apollon Formularies said.

Apollon shares were flat at 0.25 pence each in London on Tuesday afternoon.

By Sophie Rose, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Apollon Formularies PLC

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures